No headlines found.
Globe Newswire (Wed, 22-Oct 7:00 AM ET)
Curanex Pharmaceuticals Inc is engaged in discovering, developing, and commercializing botanical drugs for treating unmet medical needs in patients with inflammatory disease. Its compound, Phyto-N, is in preclinical research for six indications: ulcerative colitis, atopic dermatitis, COVID-19, type 2 diabetes, nonalcoholic fatty liver disease (NAFLD) and gout.
Curanex Pharmaceuticals trades on the NASDAQ stock market under the symbol CURX.
As of January 21, 2026, CURX stock price declined to $0.37 with 272,567 million shares trading.
CURX has a beta of 0.99, meaning it tends to be less sensitive to market movements. CURX has a correlation of 0.00 to the broad based SPY ETF.
CURX has a market cap of $10.48 million. This is considered a Sub-Micro Cap stock.
CURX support price is $.36 and resistance is $.41 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that CURX shares will trade within this expected range on the day.
